CA1326453C — Pharmaceutical composition containing pentamidine
Assigned to Fisons Corp · Expires 1994-01-25 · 32y expired
What this patent protects
Abstract Pharmaceutical Compositions An aqueous solution containing, as active ingredient, pentamidine or a pharmaceutically acceptable salt thereof, and having a pH of less than 4.5 is more stable than conventional solutions of pentamidine. The pH of the solution is preferably …
USPTO Abstract
Abstract Pharmaceutical Compositions An aqueous solution containing, as active ingredient, pentamidine or a pharmaceutically acceptable salt thereof, and having a pH of less than 4.5 is more stable than conventional solutions of pentamidine. The pH of the solution is preferably less than 4.0, more preferably less than 3.5, and especially less than 3Ø The active ingredient is preferably pentamidine isethionate and the pH of the solution is preferably adjusted by the incorporation of hydrochloric acid. The solutions may be administered directly to the lung by nebulisation and are useful in the treatment of pneumo-cystic carinii pneumonia.
Drugs covered by this patent
- Remodulin (TREPROSTINIL) · United Therap
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.